Strategies after the failure of the first anti-tumor necrosis factor α agent in rheumatoid arthritis

Autoimmunity Reviews

Volumn 9, Issue 8, 2010, Pages 574-582

  Papagoras, Charalampos ^a   Voulgari, Paraskevi V ^a   Drosos, Alexandros A ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Abatacept; Golimumab; Leflunomide; Rheumatoid arthritis; TNF inhibitors; Tocilizumab

Indexed keywords

ABATACEPT; ADALIMUMAB; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PLACEBO; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABDOMINAL INFECTION; B CELL LYMPHOMA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CROHN DISEASE; DEMYELINATING DISEASE; DISEASE ACTIVITY; DIVERTICULITIS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HEPATITIS B; HUMAN; IMMUNOGENICITY; INFECTION; INJECTION SITE REACTION; LATENT TUBERCULOSIS; LIPID BLOOD LEVEL; LOWER RESPIRATORY TRACT INFECTION; LUPUS LIKE SYNDROME; LYMPHOPROLIFERATIVE DISEASE; NEOPLASM; NEUTROPENIA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SURVIVAL RATE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOCONJUGATES; METHOTREXATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77952743228     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2010.04.002     Document Type: Review

References (71)

1. Alamanos Y., Voulgari P.V., and Drosos A.A. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum 36 (2006) 182-188
2. Sokka T., Toloza S., Cutolo M., et al., QUEST-RA Group. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther 11 (2009) R7
3. Alamanos Y., and Drosos A.A. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 4 (2005) 130-136
4. Saag K.G., Teng G.G., Patkar N.M., Anuntiyo J., Finney C., Curtis J.R., et al., American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59 (2008) 762-784
5. Combe B., Landewe R., Lukas C., Bolosiu H.D., Breedveld F., Dougados M., et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 66 (2007) 34-45
6. Brown A.K., Conaghan P.G., Karim Z., Quinn M.A., Ikeda K., Peterfy C.G., et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 58 (2008) 2958-2967
7. St Clair E.W., van der Heijde D.M., Smolen J.S., Maini R.N., Bathon J.M., Emery P., et al. Active-controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset study group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50 (2004) 3432-3443
8. Emery P., Breedveld F.C., Hall S., Durez P., Chang D.J., Robertson D., et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372 9636 (2008) 375-382
9. Breedveld F.C., Weisman M.H., Kavanaugh A.F., Cohen S.B., Pavelka K., van Vollenhoven R., et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54 (2006) 26-37
10. Emery P., Fleischmann R.M., Moreland L.W., Hsia E.C., Strusberg I., Durez P., et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 60 (2009) 2272-2283
11. Kievit W., Fransen J., Kupper H.H., van de Laar M.A.F.J., De Rooij D.J.R.A., De Gendt C.M., et al. The drug survival of adalimumab compared to etanercept and infliximab in treatment of patients with rheumatoid arthritis in daily clinical practice. Ann Rheum Dis 65 Suppl II (2006) 325
12. Gomez-Reino J.J., Carmona L., and BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 8 (2006) R29
13. Voulgari P.V., Alamanos Y., Nikas S.N., Bougias D.V., Temekonidis T.I., and Drosos A.A. Infliximab therapy in established rheumatoid arthritis: an observational study. Am J Med 118 (2005) 515-520
14. Brocq O., Roux C.H., Albert C., Breuil V., Aknouche N., Ruitord S., et al. TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease. Joint Bone Spine 74 (2007) 148-154
15. Hetland M.L., Christensen I.J., Tarp U., Dreyer L., Hansen A., Hansen I.T., et al., All Departments of Rheumatology in Denmark. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 62 (2010) 22-32
16. Finckh A., Simard J.F., Gabay C., Guerne P.A., and SCQM physicians. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 65 (2006) 746-752
17. Radstake T.R., Svenson M., Eijsbouts A.M., van den Hoogen F.H., Enevold C., van Riel P.L., and Bendtzen K. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 68 (2009) 1739-1745
18. Dore R.K., Mathews S., Schechtman J., Surbeck W., Mandel D., Patel A., et al. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 25 (2007) 40-46
19. Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Allaart C.F., van Zeben D., Kerstens P.J., Hazes J.M., et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52 (2005) 3381-3390
20. Visser K., and van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 68 (2009) 1094-1099
21. Temekonidis T.I., Georgiadis A.N., Alamanos Y., Bougias D.V., Voulgari P.V., and Drosos A.A. Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritis. Ann Rheum Dis 61 (2002) 822-825
22. Strangfeld A., Hierse F., Kekow J., von Hinueber U., Tony H.P., Dockhorn R., et al. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis 68 (2009) 1856-1862
23. St Clair E.W., Wagner C.L., Fasanmade A.A., Wang B., Schaible T., Kavanaugh A., and Keystone E.C. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46 (2002) 1451-1459
24. Takeuchi T., Miyasaka N., Inoue K., Abe T., Koike T., and RISING study. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Mod Rheumatol 19 (2009) 478-487
25. Pavelka K., Jarosová K., Suchý D., Senolt L., Chroust K., Dusek L., and Vencovský J. Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy. Ann Rheum Dis 68 (2009) 1285-1289
26. van de Putte L.B., Atkins C., Malaise M., Sany J., Russell A.S., van Riel P.L., et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 63 (2004) 508-516
27. Weinblatt M.E., Keystone E.C., Furst D.E., Moreland L.W., Weisman M.H., Birbara C.A., et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48 (2003) 35-45
28. Weinblatt M.E., Schiff M.H., Ruderman E.M., Bingham III C.O., Li J., Louie J., and Furst D.E. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study. Arthritis Rheum 58 (2008) 1921-1930
29. van der Bijl A.E., Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Ten Wolde S., Han K.H., van Krugten M.V., et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum 56 (2007) 2129-2134
30. Genovese M.C., Cohen S., Moreland L., Lium D., Robbins S., Newmark R., Bekker P., and 20000223 Study Group. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 50 (2004) 1412-1419
31. Weinblatt M., Combe B., Covucci A., Aranda R., Becker J.C., and Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 54 (2006) 2807-2816
32. Tracey D., Klareskog L., Sasso E.H., Salfeld J.G., and Tak P.P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117 (2008) 244-279
33. Taylor P.C. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr Opin Pharmacol (Feb 19 2010) [Electronic publication ahead of print]
34. Mariette X., Tubach F., Bagheri H., Bardet M., Berthelot J.M., Gaudin P., et al. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis 69 (2010) 400-408
35. Dixon W.G., Hyrich K.L., Watson K.D., Lunt M., Galloway J., Ustianowski A., et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69 (2010) 522-528
36. Wallis R.S. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 8 (2008) 601-611
37. Buch M.H., Conaghan P.G., Quinn M.A., Bingham S.J., Veale D., and Emery P. True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha?. Ann Rheum Dis 63 (2004) 1344-1346
38. Haraoui B., Keystone E.C., Thorne J.C., Pope J.E., Chen I., Asare C.G., and Leff J.A. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol 31 (2004) 2356-2359
39. Buch M.H., Bingham S.J., Bejarano V., Bryer D., White J., Reece R., et al. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept. Arthritis Rheum 57 (2007) 448-453
40. Furst D.E., Gaylis N., Bray V., Olech E., Yocum D., Ritter J., et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis 66 (2007) 893-899
41. Bombardieri S., Ruiz A.A., Fardellone P., Geusens P., McKenna F., Unnebrink K., et al., Research in Active Rheumatoid Arthritis (ReAct) Study Group. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatol (Oxford) 46 (2007) 1191-1199
42. Gullick N., Da Silva C., and Kirkham B. Failure of adalimumab in patients with rheumatoid arthritis. Arthritis Rheum 56 suppl (2007) S183
43. Navarro F., Gomez Reino J., Marsal S., Ruiz M., Hernandez-Cruz B., et al. EULAR response in clinical practice in RA patients treated with one, two or three anti-TNF alpha agents: results of an observational, prospective, cohort study in Spain. Arthritis Rheum 54 suppl II (2006) S384
44. Karlsson J.A., Kristensen L.E., Kapetanovic M.C., Gülfe A., Saxne T., and Geborek P. Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatol (Oxford) 47 (2008) 507-513
45. Blom M., Kievit W., Fransen J., Kuper I.H., den Broeder A.A., De Gendt C.M., et al. The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis. J Rheumatol 36 (2009) 2171-2177
46. Hyrich K.L., Lunt M., Watson K.D., Symmons D.P., Silman A.J., and British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 56 (2007) 13-20
47. Hjardem E., Østergaard M., Pødenphant J., Tarp U., Andersen L.S., Bing J., et al. Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?. Ann Rheum Dis 66 (2007) 1184-1189
48. Smolen J.S., Kay J., Doyle M.K., Landewé R., Matteson E.L., Wollenhaupt J., et al., GO-AFTER study investigators. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374 9685 (2009) 210-221
49. Edwards J.C., Szczepanski L., Szechinski J., Filipowicz-Sosnowska A., Emery P., Close D.R., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350 (2004) 2572-2581
50. Emery P., Fleischmann R., Filipowicz-Sosnowska A., Schechtman J., Szczepanski L., Kavanaugh A., et al., DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54 (2006) 1390-1400
51. Cohen S.B., Emery P., Greenwald M.W., Dougados M., Furie R.A., Genovese M.C., et al., REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54 (2006) 2793-2806
52. Keystone E., Emery P., Peterfy C.G., Tak P.P., Cohen S., Genovese M.C., et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 68 (2009) 216-221
53. Keystone E., Fleischmann R., Emery P., Furst D.E., van Vollenhoven R., Bathon J., et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 56 (2007) 3896-3908
54. Genovese M.C., Breedveld F.C., Emery P., Cohen S., Keystone E., Matteson E.L., et al. Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients. Ann Rheum Dis 68 (2009) 1894-1897
55. Finckh A., Ciurea A., Brulhart L., Kyburz D., Möller B., Dehler S., et al. Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 56 (2007) 1417-1423
56. Finckh A., Ciurea A., Brulhart L., Möller B., Walker U.A., Courvoisier D., et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?. Ann Rheum Dis 69 (2010) 387-393
57. Quartuccio L., Fabris M., Salvin S., Atzeni F., Saracco M., Benucci M., et al. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatol (Oxford) 48 (2009) 1557-1559
58. Choy E.H. Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 27 (2009) 510-518
59. Genovese M.C., Becker J.C., Schiff M., Luggen M., Sherrer Y., Kremer J., et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353 (2005) 1114-1123
60. Genovese M.C., Schiff M., Luggen M., Becker J.C., Aranda R., Teng J., et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 67 (2008) 547-554
61. Schiff M., Pritchard C., Huffstutter J.E., Rodriguez-Valverde V., Durez P., Zhou X., et al. The 6 month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis 68 (2009) 1708-1714
62. Fonseca J.E., Santos M.J., Canhão H., and Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 8 (2009) 538-542
63. Emery P., Keystone E., Tony H.P., Cantagrel A., van Vollenhoven R., Sanchez A., et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67 (2008) 1516-1523
64. Furst D.E., Keystone E.C., Fleischmann R., Mease P., Breedveld F.C., Smolen J.S., et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 69 Suppl 1 (2010) i2-i29
65. Calabrese L.H., Molloy E.S., Huang D., and Ransohoff R.M. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum 56 (2007) 2116-2128
66. Exarchou S.A., Voulgari P.V., Markatseli T.E., Zioga A., and Drosos A.A. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. Scand J Rheumatol 38 (2009) 328-331
67. Simon T.A., Smitten A.L., Franklin J., Askling J., Lacaille D., Wolfe F., et al. Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. Ann Rheum Dis 68 (2009) 1819-1826
68. Möttönen T., Hannonen P., Leirisalo-Repo M., Nissilä M., Kautiainen H., Korpela M., et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 353 9164 (1999) 1568-1573
69. Grigor C., Capell H., Stirling A., McMahon A.D., Lock P., Vallance R., et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364 9430 (2004) 263-269
70. Verstappen S.M., Jacobs J.W., van der Veen M.J., Heurkens A.H., Schenk Y., ter Borg E.J., et al., Utrecht Rheumatoid Arthritis Cohort Study Group. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 66 (2007) 1443-1449
71. Smolen J.S., Aletaha D., Bijlsma J.W., Breedveld F.C., Boumpas D., Burmester G., et al., T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69 (2010) 631-637